|Bid||1.6200 x 40000|
|Ask||1.7800 x 40700|
|Day's Range||1.7100 - 1.8000|
|52 Week Range||0.9500 - 6.9900|
|Beta (3Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.42|
MENLO PARK, Calif., April 18, 2019 -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three.
Geron Corporation (NASDAQ: GERN ) announced in September that Johnson & Johnson (NYSE: JNJ )'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, ...
April 8 (Reuters) - Geron Co Ltd: * SAYS CONTROLLING SHAREHOLDER PLANS TO UNLOAD UP TO 6 PERCENT STAKE IN THE COMPANY WITHIN SIX MONTHS Source text in Chinese: https://bit.ly/2IiMtRX Further company coverage: ...
MENLO PARK, Calif., April 02, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.
MENLO PARK, Calif., March 28, 2019 -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its.
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 78,400 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 20, 2019 at an exercise price of $1.77 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
MENLO PARK, Calif., March 07, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent.
Geron Corporation (GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, March 7, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2011 Chip Scarlett was appointed CEO Read More...
Geron Corporation (GERN) today announced an expansion of its leadership team with the appointment of a new chief medical officer to support the Company’s clinical drug development efforts in hematology-oncology. “As we transition to a late-stage development company, we are very pleased to welcome Dr. Aleksandra Rizo to Geron as Chief Medical Officer,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.